Helicos BioSciences Corporation

Helicos BioSciences Provides Q2 2009 Operating Highlights and Strategic Update

Helicos BioSciences Provides Q2 2009 Operating Highlights and Strategic Update

September 3, 2009

Achieves Significant Commercial and Technical Milestones

Engages Thomas Weisel Partners to Advise on Strategic Alternatives

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its operating highlights for the quarter ended June 30, 2009 and other recent developments following the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2009.

Helicos BioSciences Corporation

Helicos Sells Multiple HeliScope™ Sequencers to RIKEN Institute

Helicos Sells Multiple HeliScope™ Sequencers to RIKEN Institute

September 8, 2009

Single Molecule Sequencing Technology Will Play Integral Role in Japan's National Sequencing Center

Acceleron Pharma, Inc.

Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial

Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial

September 10, 2009

CAMBRIDGE, Mass. – September 10, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean body mass and muscle volume. The results from this randomized, placebo-controlled study were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound

Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound

September 14, 2009

Phase I Results Presented at American College of Clinical Pharmacology

Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Raises $21.5 Million Series A Extension

Alvine Pharmaceuticals Raises $21.5 Million Series A Extension

September 15, 2009

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing. New investor Panorama Capital led the financing round, joining founding investors InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.

Helicos BioSciences Corporation

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

September 16, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain new and existing investors, including Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures (the “Existing Investors”) and Ron Lowy, the Company’s chief executive officer, to raise approximately $10 million in gross proceeds in a private placement through the s

Ze-gen, Inc.

Ze-gen, Inc named a Global Cleantech 100 Clean Technology Company

Ze-gen, Inc named a Global Cleantech 100 Clean Technology Company

September 16, 2009

Recognized by the Guardian and Cleantech Group for potential and likelihood to achieve high growth and high market impact

Boston, MA — September 16, 2009 — Ze-gen, Inc., a clean energy company developing advanced gasification technology to convert waste streams into synthesis gas, today announced it has been named a Global Cleantech 100 company by Guardian News and Media and Cleantech Group™, LLC, providers of leading research, events and advisory services for the cleantech ecosystem.

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Announces $17 Million in Financing and New Board Member

Pervasis Therapeutics Announces $17 Million in Financing and New Board Member

September 16, 2009

Proceeds to Advance Ongoing Clinical Development Programs, Including PVS-10200 for the Treatment of Peripheral Arterial Disease

Yoram Richter, PhD., Joins Company's Board of Directors and Brings Significant Experience in the Cardiovascular Field

Joule Unlimited, Inc.

Joule Biotechnologies Elects Graham Allison to Board of Directors

Joule Biotechnologies Elects Graham Allison to Board of Directors

September 21, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the election of Graham Allison to its board of directors.

VisEn Medical, Inc.

VisEn Launches Reninsense680 FAST Molecular Imaging Agent to Enable in vivo Imaging Readouts of Key Biomarkers in Hypertension and Renal Function

VisEn Launches Reninsense680 FAST Molecular Imaging Agent to Enable in vivo Imaging Readouts of Key Biomarkers in Hypertension and Renal Function

September 23, 2009

Data Presented at World Molecular Imaging Congress in Montreal